BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors

Heterozygous germline mutations in BRCA2 predispose to breast and ovarian cancer. Contrary to non-cancerous cells, where BRCA2 deletion causes cell cycle arrest or cell death, tumors carrying BRCA2 inactivation continue to proliferate. Here we set out to investigate adaptation to loss of BRCA2 focus...

Descripción completa

Detalles Bibliográficos
Autores principales: Reisländer, Timo, Lombardi, Emilia Puig, Groelly, Florian J., Miar, Ana, Porru, Manuela, Di Vito, Serena, Wright, Benjamin, Lockstone, Helen, Biroccio, Annamaria, Harris, Adrian, Londoño-Vallejo, Arturo, Tarsounas, Madalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637138/
https://www.ncbi.nlm.nih.gov/pubmed/31316060
http://dx.doi.org/10.1038/s41467-019-11048-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637138/
https://www.ncbi.nlm.nih.gov/pubmed/31316060
http://dx.doi.org/10.1038/s41467-019-11048-5

Ejemplares similares